Trial reportThe journals of gerontology. Series A, Biological sciences and medical sciences2017
Allogeneic Mesenchymal Stem Cells Ameliorate Aging Frailty: A Phase II Randomized, Double-Blind, Placebo-Controlled Clinical Trial.
Trial report in The journals of gerontology. Series A, Biological sciences and medical sciences, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 5 registered trials, which are not on this map. Cited by 105 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase I/II, Randomized, Blinded and Placebo-controlled Trial to Evaluate the Safety and Potential Efficacy of Allogeneic Human Mesenchymal Stem Cell Infusion in Patients With Aging Frailty
Use of Autologous Stem/Stromal Cellular Stromal Vascular Fraction (cSVF) In Cases Of Frailty and Aging Processes Using Autologous Stem-Stromal Cell Infusion in Patients With Aging Frailty And Wellness
Open Label Study for the Use of Transcranial Ultrasound for Treatment of Age-Related Frailty
Clinical Study of Mesenchymal Stem/Stromal Cell Therapy in Frailty: a Proposed Experimental Design for Therapeutic and Mechanism Investigation
Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for the Treatment of Aging Frailty
Who cites it
105 citing papers in PubMed, 2 syntheses or guidelines pooled it, 154 citations in OpenAlex.
- Safety and Efficacy of Mesenchymal Stem Cell Therapy in Aging Frailty: A Systematic Review.International journal of molecular sciences · 2026Pooled it
- The impact of cell-based therapy on female sexual dysfunction: a systematic review and meta-analysis.Sexual medicine reviews · 2023Pooled it
- Safety and efficacy of allogeneic umbilical cord-derived mesenchymal stem cell infusion for frailty: a phase 2, single-centre, randomised, open-label controlled trial.EBioMedicine · 2026Trial
- Randomized phase 2b dose-escalation trial of stem cell therapy with laromestrocel for aging frailty.Cell stem cell · 2026Trial
- Allogeneic mesenchymal stem cell therapy with laromestrocel in mild Alzheimer's disease: a randomized controlled phase 2a trial.Nature medicine · 2025Trial
- Safety and efficacy of umbilical cord tissue-derived mesenchymal stem cells in the treatment of patients with aging frailty: a phase I/II randomized, double-blind, placebo-controlled study.Stem cell research & therapy · 2024Trial
- Results and insights from a phase I clinical trial of Lomecel-B for Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2023Trial
- NAD+-Precursor Supplementation With L-Tryptophan, Nicotinic Acid, and Nicotinamide Does Not Affect Mitochondrial Function or Skeletal Muscle Function in Physically Compromised Older Adults.The Journal of nutrition · 2021Trial
- Article
- A Mechanism-Based Framework for Anti-Aging Strategies: From Metabolic Regulation to Senotherapy and Stem Cell-Based Interventions.Aging cell · 2026Review
- Nanotechnological Strategies to Promote Skeletal Muscle Regeneration in Aging.International journal of molecular sciences · 2026Review
- Combatting ventilator induced diaphragm dysfunction with human bone marrow mesenchymal stromal cell-derived extracellular vesicles.Skeletal muscle · 2026Article
- Mesenchymal stem cells for recurrent miscarriage.Journal of translational medicine · 2026Review
- The autophagy-senescence axis as a threshold model of aging and therapeutic targeting.Redox biology · 2026Review
- Exploring the nexus between inflammation and mobility through the lens of healthy aging: current scenario and future perspectives.Aging clinical and experimental research · 2026Review
- Musculoskeletal ultrasound-guided cellular therapy: Current applications and future directions in skeletal muscle regeneration.Iranian journal of basic medical sciences · 2026Review
- Stem cell dysfunction and rejuvenation strategies in ageing: emerging advances in regenerative medicine.Frontiers in cell and developmental biology · 2026Review
- Immunomodulatory effects of HUC-MSCs therapy: enhancing adaptive and innate immune responses in aging frailty.Frontiers in immunology · 2026Article
- Exercise-Activated Mesenchymal Stem Cells: A Translational Strategy for Age-Related Sarcopenia Management.Stem cell reviews and reports · 2025Review
- Impact of cell culture transition on adipose-derived mesenchymal stromal cells: Multi-omics analysis of small- vs large-scale production.Molecular therapy. Methods & clinical development · 2025Article
45 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
30 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAging frailty, characterized by decreased physical and immunological functioning, is associated with stem cell depletion. Human allogeneic mesenchymal stem cells (allo-hMSCs) exert immunomodulatory effects and promote tissue repair.
methodsThis is a randomized, double-blinded, dose-finding study of intravenous allo-hMSCs (100 or 200-million [M]) vs placebo delivered to patients (n = 30, mean age 75.5 ± 7.3) with frailty. The primary endpoint was incidence of treatment-emergent serious adverse events (TE-SAEs) at 1-month postinfusion. Secondary endpoints included physical performance, patient-reported outcomes, and immune markers of frailty measured at 6 months postinfusion.
resultsNo therapy-related TE-SAEs occurred at 1 month. Physical performance improved preferentially in the 100M-group; immunologic improvement occurred in both the 100M- and 200M-groups. The 6-minute walk test, short physical performance exam, and forced expiratory volume in 1 second improved in the 100M-group (p = .01), not in the 200M- or placebo groups. The female sexual quality of life questionnaire improved in the 100M-group (p = .03). Serum TNF-α levels decreased in the 100M-group (p = .03). B cell intracellular TNF-α improved in both the 100M- (p < .0001) and 200M-groups (p = .002) as well as between groups compared to placebo (p = .003 and p = .039, respectively). Early and late activated T-cells were also reduced by MSC therapy.
conclusionIntravenous allo-hMSCs were safe in individuals with aging frailty. Treated groups had remarkable improvements in physical performance measures and inflammatory biomarkers, both of which characterize the frailty syndrome. Given the excellent safety and efficacy profiles demonstrated in this study, larger clinical trials are warranted to establish the efficacy of hMSCs in this multisystem disorder. CLINICAL
trial registrationwww.clinicaltrials.gov: CRATUS (#NCT02065245).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.